• Favourable safety profile of eftilagimod alpha in combination with pembrolizumab
• Deep and durable responses have been observed with tumour shrinkage in 56% and 66% of patients in part A and B respectively
• Disease Control Rate of 66% of patients in each Part A and B (24 patients in total)
• Favourable safety profile of eftilagimod alpha in combination...
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
-0.005(1.59%) |
Mkt cap ! $450.9M | |||
| Open | High | Low | Value | Volume |
| 31.5¢ | 31.8¢ | 31.0¢ | $897.5K | 2.872M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 79201 | 31.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.5¢ | 138883 | 3 |
View Market Depth
| Last trade - 16.10pm 08/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |